Goldman maintains Sell rating on Incyte after Jakafi results LINK
Seeking Alpha Market Currents
Goldman maintains Sell rating on Incyte after Jakafi results
"The Street is assigning value to Jakafi in other solid cancers (e.g., lung cancer), which we believe is premature given lack of data and limited visibility on subgroup criteria," Goldman's Navdeep Singh says, regarding the huge run up in shares of Incyte (INCY -4.5%) following the release of data from a Phase 2 pancreatic cancer study.
Goldman maintains its Sell rating on the shares.
Price target is $26, some 28% lower than Wednesday's close.
Never fails! Right when they dropped the target to 17$ a few months back, incy jumped into the 20s and never looked back. They clearly just lowball stocks so people sell them and they can increase their positions with suckers former shares.
How is that not illegal? They're definitely the worst with this kind of practice. Just look at some other stocks targets. They do it all the time